Healthcare and Life Science
3 Steps for cell & gene therapy medical affairs teams to provide strategic value
A phrase often recited within the pharmaceutical and biotechnology industries in recent years is that medical affairs is the third strategic pillar of success, along with R&D and commercial. Ongoing advancements in the cell and gene therapy sector have further highlighted the critic...
Yourgene Health becomes a PacBio Compatible Partner: enabling PacBio customers to optimise size selection for long-read sequencing libraries
Yourgene’s LightBench® instrument offers precise and accurate size selection of PacBio® SMRTbell® sequencing libraries increasing HiFi sequencing yields ...
First product incorporating Arecor’s Arestat Technology, AT220, launches in Europe
First commercial sale triggers milestone payment and future royalties to Arecor
Local psychiatrists publish expert guidance in new books
Experts at Cambridgeshire and Peterborough NHS Foundation Trust (CPFT), Cambridge University and the NIHR Applied Research Collaboration East of England (NIHR ARC EoE) have contributed two new textbooks to the psychiatry canon, which have been published today. ...
The Paradigm Shift: Navigating the emergence of value-based contracts for future gene therapies
Value-based contracting (VBC) has been difficult to execute in the pharmaceutical arena, especially in the gene therapy space. This has been driven by several factors, including the lack of long-term data, the imbalance of upside and downside risk between manufacturers and payers, and d...
A longitudinal perspective on innovation
There is growing interest in the innovation process in the biopharmaceutical industry, with particular public scrutiny around the composition of research and development (R&D) spending and the role of intellectual property. This process is commonly characterized as involving a mixtu...
Oncology vaccines: Are they positioned for PMA success?
With combinations taking center stage following the initial influx of immune checkpoint inhibitor monotherapies, the authors look ahead to the potential of mRNA vaccines in oncology and describe the pricing and market access opportunities and challenges that may await current and future...
The burden of non-specific pain disorder in US women
Based on existing evidence on the delay, lack of recognition, and burden of pain conditions commonly afflicting women (specifically endometriosis, PCOS, fibromyalgia, IBS or migraines), CRA sought to understand how being diagnosed with these conditions impacts women’s mental health and ...
The longitudinal history of medicines innovation: Part two
The second of a two-part article, CRA’s Life Sciences Practice team, along with experts at The Janssen Pharmaceutical Companies of Johnson & Johnson, recently conducted a landscape review of how complex pharmaceutical innovation happens in practice, leveraging three therapy area cas...
The longitudinal history of medicines innovation: Part One
This article is originally published in PharmaPhorum. As we move forwards in public discussions on pharmaceutical innovation and its value to patients and society, it is helpful to ground conversations in a solid understanding of how medicines development occurs. ...